TDTerry Van Dyke

Terry Van Dyke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Terry Van Dyke has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Glenn Merlino

    Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

    3 shared publications
  • Chunyu Yang

    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Debra Gilbert

    Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    2 shared publications
  • Philip L. Martin

    Center for Advanced Preclinical Research, SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America

    2 shared publications
  • Serguei Kozlov

    Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Frederick, MD 21702

    2 shared publications
  • Simone Difilippantonio

    Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Frederick, MD 21702

    2 shared publications

Latest Publications

  • Top Cited Papers

    Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

    by Chi-Ping Day, Glenn Merlino, Terry Van Dyke


  • Open Access

    Carcinoma Initiation via Rb Tumor Suppressor Inactivation: A Versatile Approach to Epithelial Subtype-Dependent Cancer Initiation in Diverse Tissues

    by Yurong Song, Debra Gilbert, T. Norene O’sullivan, Chunyu Yang, Wenqi Pan, Alisan Fathalizadeh, Lucy Lu, Diana C. Haines, Philip L. Martin, Terry Van Dyke

    Carcinomas arise in a complex microenvironment consisting of multiple distinct epithelial lineages surrounded by a variety of stromal cell types. Understanding cancer etiologies requires evaluating the relationship among cell types during disease initiation and through progression. Genetically engineered mouse (GEM) models facilitate the prospective examination of early oncogenic events, which is not possible in humans. Since most solid tumors harbor aberrations in the RB network, we developed an inducible GEM approach for the establishment and assessment of carcinoma initiation in a diverse range of epithelial tissues and subtypes upon inactivation of RB-mediated tumor suppression (RB-TS). The system allows independent assessment of epithelial subtypes that express either cytokeratins (K) 18 or 19. By Cre-dependent expression of a protein that dominantly inactivates RB and functionally redundant proteins p107 and p130, neoplasia could be initiated in either K18 or K19 expressing cells of numerous tissues. By design, because only a single pathway aberration was engineered, carcinomas developed stochastically only after long latency. Hence, this system, which allows for directed cell type-specific carcinoma initiation, facilitates further definition of events that can progress neoplasms to aggressive cancers via engineered, carcinogen-induced and/or spontaneous evolution.


  • Evolutionary etiology of high-grade astrocytomas

    by Yurong Song, Qian Zhang, Burak Kutlu, Simone Difilippantonio, Ryan Bash, Debra Gilbert, Chaoying Yin, T. Norene O’sullivan, Chunyu Yang, Serguei Kozlov, et al.

    Glioblastoma (GBM), the most common brain malignancy, remains fatal with no effective treatment. Analyses of common aberrations in GBM suggest major regulatory pathways associated with disease etiology. However, 90% of GBMs are diagnosed at an advanced stage (primary GBMs), providing no access to early disease stages for assessing disease progression events. As such, both understanding of disease mechanisms and the development of biomarkers and therapeutics for effective disease management are limited. Here, we describe an adult-inducible astrocyte-specific system in genetically engineered mice that queries causation in disease evolution of regulatory networks perturbed in human GBM. Events yielding disease, both engineered and spontaneous, indicate ordered grade-specific perturbations that yield high-grade astrocytomas (anaplastic astrocytomas and GBMs). Impaired retinoblastoma protein RB tumor suppression yields grade II histopathology. Additional activation of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) network drives progression to grade III disease, and further inactivation of phosphatase and tensin homolog (PTEN) yields GBM. Spontaneous missense mutation of tumor suppressor Trp53 arises subsequent to KRAS activation, but before grade III progression. The stochastic appearance of mutations identical to those observed in humans, particularly the same spectrum of p53 amino acid changes, supports the validity of engineered lesions and the ensuing interpretations of etiology. Absence of isocitrate dehydrogenase 1 (IDH1) mutation, asymptomatic low grade disease, and rapid emergence of GBM combined with a mesenchymal transcriptome signature reflect characteristics of primary GBM and provide insight into causal relationships. Significance High-grade astrocytomas (HGAs), including glioblastomas (GBMs), are the most common human brain tumors, and they remain fatal with no effective treatment. The most prevalent form, primary GBM, presents clinically as advanced disease, thus providing no access to or understanding of early stages. We report a comprehensive study in the mouse that establishes causal relationships and an evolutionary etiology in HGA development. Events yielding disease, both engineered and spontaneous, indicate grade-specific roles culminating in the development of GBMs with characteristics of primary GBMs, including molecular alignment with the mesenchymal subclass, asymptomatic early disease, and rapid emergence of high-grade aggressive cancer. These genetically engineered models provide a path to basic understanding of disease etiology and a window into diagnostic and therapeutic discovery.


  • Meeting report: The future of preclinical mouse models in melanoma treatment is now

    by Glenn Merlino, Keith Flaherty, Nicolas Acquavella, Chi‐Ping Day, Andrew Aplin, Sheri Holmen, Suzanne Topalian, Terry Van Dyke, Meenhard Herlyn


  • Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response

    by Zoë Weaver, Simone Difilippantonio, Julian Carretero, Philip L. Martin, Rajaa El Meskini, Anthony J. Iacovelli, Michelle Gumprecht, Alan Kulaga, Theresa Guerin, Jerome Schlomer, et al.

    Patients with lung cancer with activating mutations in the EGF receptor (EGFR) kinase, who are treated long-term with tyrosine kinase inhibitors (TKI), often develop secondary mutations in EGFR associated with resistance. Mice engineered to develop lung adenocarcinomas driven by the human EGFR T790M resistance mutation are similarly resistant to the EGFR TKI erlotinib. By tumor volume endpoint analysis, these mouse tumors respond to BIBW 2992 (an irreversible EGFR/HER2 TKI) and rapamycin combination therapy. To correlate EGFR-driven changes in the lung with response to drug treatment, we conducted an integrative analysis of global transcriptome and metabolite profiling compared with quantitative imaging and histopathology at several time points during tumor progression and treatment. Responses to single-drug treatments were temporary, whereas combination therapy elicited a sustained response. During tumor development, metabolomic signatures indicated a shift to high anabolic activity and suppression of antitumor programs with 11 metabolites consistently present in both lung tissue and blood. Combination drug treatment reversed many of the molecular changes found in tumored lung. Data integration linking cancer signaling networks with metabolic activity identified key pathways such as glutamine and glutathione metabolism that signified response to single or dual treatments. Results from combination drug treatment suggest that metabolic transcriptional control through C-MYC and SREBP, as well as ELK1, NRF1, and NRF2, depends on both EGFR and mTORC1 signaling. Our findings establish the importance of kinetic therapeutic studies in preclinical assessment and provide in vivo evidence that TKI-mediated antiproliferative effects also manifest in specific metabolic regulation. Cancer Res; 72(22); 5921–33. ©2012 AACR.


  • It Takes a (Dysfunctional) Village to Raise a Tumor

    by Karlyne M. Reilly, Terry Van Dyke